Associate Professor Marion Mafham
Clinical Research Fellow, CTSU
- Honorary Consultant Nephrologist, Oxford Kidney Unit
Marion Mafham studied medicine at the University of Edinburgh (1992-1998). In 2003, she joined the Renal Studies Group at CTSU for 3 years as a research fellow, working on the Study of Heart and Renal Protection. During this time she completed an MD thesis examining the relationship between measures of kidney function and cardiovascular risk factors and cardiovascular events. After completing her specialist training in Nephrology, she returned to CTSU in 2013, to work with Professor Jane Armitage in the Heart Studies Group. She is also an Honorary Consultant Nephrologist in the Oxford University Hospitals NHS trust.
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2022), Lancet, 399, 143 - 151
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2021), The Lancet. Respiratory medicine, 9, 1419 - 1426
Performance of the UKPDS Outcomes Model 2 in a contemporary UK type 2 diabetes trial cohort
Keng MJ. et al, (2021), Value in Health
What is the association of COVID-19 with heart attacks and strokes?
Mafham M. and Baigent C., (2021), Lancet, 398, 561 - 563
The RECOVERY trial: cardiovascular implications of a large, simple randomized trial in COVID-19.
Pessoa-Amorim G. and Mafham MM., (2021), Cardiovasc Res, 117, e110 - e113